EICHORCondition: Multiple Myeloma · Sponsor: Hoffmann-La Roche
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Colorado | Aurora, Colorado, United States | — |
| Mayo Clinic-Jacksonville | Jacksonville, Florida, United States | — |
| University of Maryland Greenebaum Cancer Center | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | — |
| Icahn School of Medicine at Mount Sinai (ISMMS) | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Tennessee Oncology - Nashville | Nashville, Tennessee, United States | — |
| Hunstman Cancer Institute | Salt Lake City, Utah, United States | — |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | — |
| St Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | — |
| UZ Leuven Gasthuisberg | Leuven, Belgium | — |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05535244